Nanomedical Diagnostics recently announced the launch of the new graphene-enhanced NHS Agile biosensor chip. The new chip reportedly reduces the number of steps needed to gain kinetic binding data for a wide range of molecules, including small and large molecules, peptides, proteins, and antibodies. NHS biosensors are designed for use on the company’s Agile R100 label-free personal assay system.
“Many pharmaceutical companies have established protocols for studying molecules using standard amine-linker chemistry,” noted Nanomedical Diagnostics' CEO. “However, traditional methods using these protocols require numerous steps on complicated machines that make experiments difficult to run and prone to variability. Our new NHS biosensor combined with the single-sample format Agile R100 allows researchers to leverage these tried and true techniques, but reduces the process greatly compared to prior systems. Both experiment complexity and results variability are decreased, which gives all researchers the ability to gain reliable label-free kinetic binding data for their molecules at their benchtop, on their schedule.”